Jump to main content
Jump to site search


Nanoparticles decorated with granulocyte-colony stimulating factor for targeting myeloid cells

Abstract

Dysregulated myeloid cell activity underlies a variety of pathologies, including immunosuppression in malignant cancers. Current treatments to alter myeloid cell behavior also alter other immune cell subpopulations and nonimmune cell types with deleterious side effects. Therefore, improved selectivity of myeloid treatment is an urgent need. To meet this need, we demonstrate a novel, targeted nanoparticle system that achieves superior myeloid selectivity both in vitro and in vivo. This system comprises: (1) granulocyte-colony stimulating factor (G-CSF) as a targeting ligand to promote accumulation in myeloid cells, including immunosuppressive myeloid-derived suppressor cells (MDSCs); (2) an albumin nanoparticle 100-120 nm in diameter that maintains morphology and drug payload in simulated physiological conditions; and (3) a fluorophore that enables nanoparticle tracking and models a therapeutic molecule. Here, we show that this strategy achieves high myeloid uptake in mixed primary immune cells and that nanoparticles successfully infiltrate the 4T1 triple-negative breast tumor murine microenvironment, where they preferentially accumulate in myeloid cells in a mouse model. Further development will realize diagnostic myeloid cell tracking applications and therapeutic delivery of myeloid-reprogramming drugs.

Back to tab navigation

Supplementary files

Article information


Submitted
30 Jul 2019
Accepted
29 Dec 2019
First published
03 Jan 2020

Nanoscale, 2020, Accepted Manuscript
Article type
Paper

Nanoparticles decorated with granulocyte-colony stimulating factor for targeting myeloid cells

K. Margulis, A. Honkala, I. Kalashnikova, S. E. Noll, M. Hill, R. N. Zare and B. R. Smith, Nanoscale, 2020, Accepted Manuscript , DOI: 10.1039/C9NR06494J

Social activity

Search articles by author

Spotlight

Advertisements